Abnehmmedikamente

The Weight Loss Drugs theme covers pharmacologic therapies targeting obesity and metabolic disorders, spanning prescription anti-obesity agents and adjacent metabolic indications. Core tracks include incretin-based therapies (GLP-1, GIP/GLP-1 co-agonists), next-generation multi-agonists and amylin analogs, oral and long-acting formulations, lifecycle and combo strategies, plus manufacturing scale-up and access dynamics across diabetes, cardiovascular risk, and NASH comorbidities.The sector's total market cap is 1638.64 billion USD, with a 24h change of +0.42%. Among 5 constituents, 5 are up (100.00%) and 0 are down (0%). The top gainer is Novo-Nordisk A/S (NVO), with a 24h increase of +1.52%.Leaders in obesity therapeutics guided the group higher, while breadth stayed mixed with smaller names lagging. Near term, favor proven innovators; medium term, pace allocations with earnings clarity and interest‑rate trends.